Bundle for the prevention and management of complications of neutropenia in cancer patients.

Rosilene Aparecida Costa Amaral,Edilene Aparecida Araújo Da Silveira,Patrícia Peres De Oliveira,Juliano Teixeira Moraes,Deborah Franscielle Da Fonseca,Kelli Borges Dos Santos,Thalyta Cristina Mansano Schlosser

doi:10.1590/0034-7167-2020-0195

Rosilene Aparecida Costa Amaral, Edilene Aparecida Araújo Da Silveira + Show 5 more

Open Access

https://doi.org/10.1590/0034-7167-2020-0195

Copy DOI

Abstract

to construct and assess bundle content for the prevention and management of complications in neutropenia in cancer patients. a methodological study developed in four stages: scoping review; bundle construction; material assessment by experts (developed according to Pasquali's psychometry); pilot test in a High Complexity Assistance Unit in Oncology. For content assessment, the Delphi technique was applied in two rounds and those items with Content Validation Coefficient (CVC)> 0.78 and agreement> 80.0% were considered valid. Data were analyzed using descriptive and inferential statistics. all bundle requirements reached agreement between judges above 80.0%, in addition to statistically significant levels of assessment. At the end of the Delphi technique, bundle was significantly valid with CVC = 0.92 and CVC = 0.93, respectively. bundle content proved to be valid and highly credible.

Highlights

IntroductionThere are several forms of treatment for malignant neoplasia, such as antineoplastic chemotherapy (CT), biological therapy, external and intraoperative radiation therapy, radioiodotherapy, brachytherapy, surgeries, in addition to hematopoietic stem cell transplantation (HSCT)(1-2)
There are several forms of treatment for malignant neoplasia, such as antineoplastic chemotherapy (CT), biological therapy, external and intraoperative radiation therapy, radioiodotherapy, brachytherapy, surgeries, in addition to hematopoietic stem cell transplantation (HSCT)(1-2).CT consists of using chemical substances, alone or in combination, aiming at treating malignant neoplasms acting at the cellular level, interfering in the process of cell growth and division
It is understood that the participation of experienced judges and involved in assistance, management and research is relevant for the assessment of instruments to be applied in practice, as this study proposed when assessing a bundle for prevention and management complications of neutropenia in cancer patients

Summary

Introduction

There are several forms of treatment for malignant neoplasia, such as antineoplastic chemotherapy (CT), biological therapy, external and intraoperative radiation therapy, radioiodotherapy, brachytherapy, surgeries, in addition to hematopoietic stem cell transplantation (HSCT)(1-2). CT consists of using chemical substances, alone or in combination, aiming at treating malignant neoplasms acting at the cellular level, interfering in the process of cell growth and division. It constitutes a therapy without specificity; it does not selectively or exclusively destroy tumor cells, causing toxicities and undesirable effects. CT is an indispensable treatment option in cancer treatment(3-4). This therapy causes myelosuppression, favoring febrile neutropenia (FN) and infections. FN occurs when the absolute neutrophil count is less than 1,000 mm, usually between 7 to 14 days after CT session, called the NADIR period(5)

Objectives

Methods

Results

Discussion

Conclusion